Extramedullary involvement in multiple myeloma

Haematologica

Volumn 97, Issue 11, 2012, Pages 1618-1619

  Bladé, Joan ^a   de Larrea, Carlos Fernández ^a   Rosiñol, Laura ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CD56 ANTIGEN; CHEMOKINE RECEPTOR; HERMES ANTIGEN; LENALIDOMIDE; M PROTEIN; TETRASPANIN; THALIDOMIDE; VERY LATE ACTIVATION ANTIGEN 4;

AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW; CHROMOSOME ABERRATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE ASSOCIATION; EDITORIAL; HUMAN; INCIDENCE; METASTASIS; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; OVERALL SURVIVAL; PLASMACYTOMA; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT;

FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MULTIPLE MYELOMA; POSITRON-EMISSION TOMOGRAPHY; SKIN NEOPLASMS; SOFT TISSUE NEOPLASMS;

EID: 84868565193     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.078519     Document Type: Editorial

References (20)

1. Ghobrial IM. Myeloma as a model for the process of metastasis: implications for therapy. Blood. 2012;120(1):20-30.
2. Bladé J, Fernández de Larrea C, Rosiñol L, Cibeira MT, Jimenez R, Powles R. Soft-Tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol. 2011;29(28):3805-12.
3. Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009;113(22):5412-7.
4. Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood. 2009;113(22):5418-22.
5. International Myeloma Working Group. Criteria for classification of monoclonal gammopathies, multiple myeloma and related disorders. Br J Haematol. 2003;121(5):749-57.
6. Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1,003 consecutive patients. Ann Oncol. 2009;21(2):325-30.
7. Wu P, Davies FE, Boyd K, Thomas K, Dines S, Saso RM, et al. The impact of extramedullary disease at presentation in outcome of myeloma. Leuk Lymphoma. 2009;50(2):230-5.
8. Bladé J, Lust J, Kyle RA. Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 patients. J Clin Oncol. 1994;12(11):2398-404.
9. Bladé J, Kyle RA, Greipp PR. Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. Br J Heamatol. 1996;93(2):345-51.
10. Raanani P, Shpilberg O, Ben-Bassat I. Extramedullary disease and targeted therapies in haematological malignancies-is the association real? Ann Oncol. 2007;18(1):7-12.
11. De Larrea CF, Rosiñol L, Cibeira MT, Rozman M, Rovira M, Bladé J. Extensive soft-tissue involvement by plasmablastic myeloma arising from displaced humeral fractures. Eur J Haematol. 2010;85(5):448-51.
12. Dimopoulos M, Terpos E, Comenzo RL, Tosi P, Beksac M, Sezer O, et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia. 2009; 23(9):1545-54.
13. Rosiñol L, Oriol A, Teruel AI, Hernández D, López-Jiménez J, de la Rubia J, et al. Superiority of bortezomib, thalidomide and dexamethasone (VTD) as induction pre-transplantation therapy in multiple myeloma: a randomized phase III PETHEMA/GEM study. Blood. 2012;120(8):1589-96.
14. Rosiñol L, Cibeira MT, Bladé J, Esteve J, Aymerich M, Rozman M, et al. Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica. 2004;89(7):832-6.
15. Avigdor A, Raanani P, Levi I, Hardan I, Ben-Bassat I. Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma. Leuk Lymphoma. 2001;42(4):683-7.
16. Rosiñol L, Cibeira MT, Uriburu C, Yantorno S, Salamero O, Bladé J, Montserrat E. Bortezomib: an effective agent in extramedullary disease in multiple myeloma. Eur J Haematol. 2006;76(5):405-8.
17. Usmani SZ, Heuck C, Mitchell A, Szymonifka J, Nair B, Hoering A, et al. Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica. 2012;97(11):1761-7.
18. Mitsiades CS, Anderson KC, Carrasco DR. Mouse models of human myeloma. Hematol Oncol Clin North Am. 2007;21(6):1051-69.
19. Qi CF, Zhou JX, Lee CH, Naghashfar Z, Xiang S, Kovalchuk AL, et al. Anaplastic, plasmablastic, and plasmacytic plasmacytomas of mice: relationships of human plasma cell neoplasm and late-stage differentiation of normal B cells. Cancer Res. 2007;67(6):2439-47.
20. Campbell RA, Manyak SJ, Yang HH, et al. LAG-lambda-1: a clinically relevant drug resistant human multiple myeloma tumor murine model that enables rapid evaluation of treatments for multiple myeloma. Int J Oncol. 2006:28(6):1409-17.